首页> 外文期刊>INAE Letters >Prototype of a Smart Microfluidic Platform for the Evaluation of SARS-Cov-2 Pathogenesis, Along with Estimation of the Effectiveness of Potential Drug Candidates and Antigen-Antibody Interactions in Convalescent Plasma Therapy
【24h】

Prototype of a Smart Microfluidic Platform for the Evaluation of SARS-Cov-2 Pathogenesis, Along with Estimation of the Effectiveness of Potential Drug Candidates and Antigen-Antibody Interactions in Convalescent Plasma Therapy

机译:用于评估SARS-COV-2发病机制的智能微流体平台的原型,以及估算潜在药候选者和抗原 - 抗体相互作用在临时血浆治疗中的有效性

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Originating in China during December 2019, the novel corona-virus, SARS-CoV-2, has created mayhem worldwide in a very short time. The outbreak has been so rapid and widespread that the only option to treat the patients was administering drugs already available in the market like chloroquine/hydroxychloroquine (an antimalarial drug) and remedesivir. A large number of patients have been cured but the attribution to survival by these drugs has been controversial. Till date, we do not have any specific drug or vaccine available for COVID-19 and the pandemic seems to be far from over. To handle the current challenges posed by the outbreak effectively, we need to employ innovative interdisciplinary approaches. Organ-on-chip (OOC), particularly lung-on-chip, is one such approach which combines the potential of microfluidics, cell culture and molecular biology into a single miniaturised platform. The device is realized to be capable of simulating in-vivo physiological responses of an organ. In the current study, an OOC, which is a multichannel 3D cell culture microfluidic device, is made via soft lithography technique, using polydimethylsiloxane-polymer and diverse polymeric porous/semipermeable membranes. Several polymer membranes i.e. PDMS, polyvinylidene fluoride (PVDF), nitrocellulose, polyester etc., integrated into the microdevices, were efficiently explored to realize their better cell-adhesion and viability property. We also propose for the application of a simple, smart and cost-effective lung-on-chip platform to study the SARS-CoV-2 pathogenesis in humans, drug toxicity testing and provide insights into antigen-antibody interactions. This platform will enable us to study multiple phenomena at a micro-level generating more reliable data and a better understanding of the underlying mechanisms of SARS-CoV-2 infection and pathogenesis.
机译:2019年12月在2019年12月,新的Corona-Virus,SARS-COV-2,在很短的时间内创造了Mayhem。爆发是如此迅速,普遍普遍认为,患者唯一的选择是在氯喹/羟氯喹(一种抗疟药)和Remedesivir等市场中已经提供的药物。许多患者已被治愈,但这些药物的生存归因是有争议的。到目前为止,我们没有任何可用于Covid-19的特定药物或疫苗,大流行似乎远远差不多。为了处理爆发有效地提出的当前挑战,我们需要采用创新的跨学科方法。片内(OOC),特别是肺片,是一种这样的方法,它将微流体,细胞培养物和分子生物学的潜力结合到单一的小型化平台中。该装置实现能够模拟器官的体内生理反应。在目前的研究中,通过柔软的光刻技术,使用多二甲基硅氧烷 - 聚合物和多种聚合物多孔/半透膜来制造作为多通道3D细胞培养微流体装置的OOC。有效地探索了集成在微生物中的几种聚合物膜,聚偏氟乙烯(PVDF),硝化纤维素,聚酯等,以实现其更好的细胞粘附和活性性能。我们还提出应用简单,智能和经济高效的肺片平台,研究人类的SARS-COV-2发病机制,药物毒性测试,并向抗原抗体相互作用提供见解。该平台将使我们能够在微级生成多种现象,从而更好地了解SARS-COV-2感染和发病机制的潜在机制。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号